On October 13, 2025, AbbVie announced it received approval from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) for RINVOQ® (upadacitinib). This approval expands the drug's indication for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Previously, RINVOQ was approved for patients who did not respond to or could not tolerate TNF blockers. The updated label now allows RINVOQ to be prescribed to patients who have tried at least one other approved systemic therapy, even before a TNF blocker, if TNF blockers are considered clinically inadvisable. This change provides greater flexibility for physicians and broadens the treatment landscape for patients with these chronic inflammatory bowel diseases. In reaction to the news, AbbVie's shares (ABBV) reportedly rose by 1%, and retail investor sentiment on the Stocktwits platform shifted from 'neutral' to 'bullish'.